Exoskeleton pioneer Bionik Labs raises $6.2 million
TORONTO – Bionik Laboratories Corp., a Delaware corporation, has announced that it acquired Bionik Laboratories, Inc., a Toronto corporation, and completed the sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately $6.2 million.
Bionik Laboratories is an innovative medical-robotics company that develops healthcare solutions for patients with restricted physical mobility.
Peter Bloch, CEO of Bionik Laboratories, stated, “Our team at Bionik Labs is focused and dedicated to deploying cutting edge solutions that will assist mobility impaired people. As a company, we are committed to improving the lives of hundreds of thousands of people and we are excited to be in the forefront of this new and developing technology.”
The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered, sold or resold absent registration or an applicable exemption from registration under such Act.
The Company intends to file a Current Report on Form 8-K with the Securities and Exchange Commission with more detailed information in accordance with the SEC rules.
About Bionik Laboratories
Founded in 2010 by Michal Prywata and Thiago Caires, Bionik Laboratories, a medical device and robotics company, core focus is robotic exoskeleton technology for users with mobility impairments. The technology provides the ability for users to rehabilitate effectively by being able to actually walk with the help of the technology. Bionik Laboratories has researched, developed and tested its primary product, The ARKE, an exoskeleton device that allows paraplegics and other mobility impaired individuals to stand up, walk and rehabilitate in a more effective way than current manual rehabilitation methods.